Filter Releases
 
News Releases
Date Title and Summary View
Jan 5, 2018
TUSTIN, Calif., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that it is changing its name to Avid Bioservices, Inc. as part of its t...
Jan 2, 2018
TUSTIN, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 10...
Dec 26, 2017
TUSTIN, Calif., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced the appointment of Roger J. Lias, Ph.D., as the company's new president and chief executive officer.  Dr. Lias, who h...
Dec 11, 2017
-- Avid Bioservices Records Revenues of $12.8 Million in the Second Quarter of FY2018 --             -- Transition to a Dedicated CDMO Business Nearing Completion -- TUSTIN, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing a...
Dec 7, 2017
TUSTIN, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Preferr...
Dec 4, 2017
TUSTIN, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on helping improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of...
Nov 28, 2017
TUSTIN, Calif. and CHICAGO, Ill., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP) ("Peregrine") and Ronin Trading, LLC and SW Investment Management LLC (together, "Ronin/SWIM"), collectively Peregrine's largest stockholder, today announced that they have entered into a settlement agreement (the "Agre...
Nov 13, 2017
TUSTIN, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP) today announced that its 2017 Annual Meeting of Stockholders will be held on January 18, 2018, at 14191 Myford Road, Tustin, California 92780, located within the company's manufacturing campus. Holders of the company's common stock at th...
Oct 24, 2017
TUSTIN, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on helping improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Patrick Walsh as an independent member of th...
Oct 19, 2017
TUSTIN, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on helping improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Mark R. Bamforth as an independent  member o...
Sep 11, 2017
-- Avid Bioservices Records Revenues of $27 Million in the First Quarter of FY2018 -- -- Roger Lias, Ph.D., Appointed President of Avid Bioservices as Company Continues Transition to a CDMO Focused Business -- -- Supported by Recent Positive Data, Company is Pursuing Strategic Options for its Research and Development Assets -- TUSTIN, Calif....
Sep 11, 2017
TUSTIN, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and through its proprietary R&D pipeline, today announced the appointment of Roger J...
Sep 7, 2017
TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced dosing of the first pati...
Sep 6, 2017
TUSTIN, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report fina...
Sep 5, 2017
TUSTIN, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Prefer...
Aug 11, 2017
Reductions in R&D, manufacturing and administrative personnel Anticipated annual cost savings of over $7 million TUSTIN, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) today announced that it has reduced its overall workforce by 60 employees (or 20%) as part of its series of planned strategic actions...
Jul 31, 2017
Plans to Expand Board of Directors to Add CDMO and Biologics Industry Expertise Search for a Dedicated President to Head Avid Bioservices CDMO Business to Commence Continues to Evaluate Strategic Options for Advancing R&D Business TUSTIN, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) today announce...
Jul 14, 2017
-- Avid Achieves Year-Over-Year Topline Revenue Growth of 30% Exceeding $57 Million -- Modified from Kallinteris NL et. al., AACR 2017 ...
Jul 13, 2017
TUSTIN, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today confirmed that Ronin Trading, LLC and SW Investment Management LLC (together, "Ronin/SWIM") submitted three candidates for election to the Peregrine Board of Directors at the Company's Annual Meeting of Stockholders. The Company issued the follow...
Jul 7, 2017
TUSTIN, Calif., July 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report finan...
Jul 7, 2017
TUSTIN, Calif., July 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that a previously approved 1-for-7 reverse split of its outstanding shares of common stock will take effect at 5:00pm EDT on Friday, July 7, 2017.  Peregrine's common stock will open for trading on the NASDAQ Capital Mark...
Jun 6, 2017
TUSTIN, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Preferr...
Jun 5, 2017
-- Negative PD-L1 Expression was Associated with a Significantly Longer Median Overall Survival Compared to Positive PD-L1 Expression in Patients Receiving Docetaxel Plus Bavituximab -- -- Presented Results Support Hypothesis that Bavituximab May Demonstrate Greater Effect in "Cold" Tumors Expressing Low to No PD-L1 -- TUSTIN, Calif., June ...
Apr 4, 2017
-- SUNRISE Data Analysis Demonstrates Statistically Significant Overall Survival (OS) Improvement in Patients Receiving Bavituximab plus Docetaxel and Subsequent Immunotherapy Compared to Placebo plus Docetaxel and Subsequent Immunotherapy -- TUSTIN, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NA...
Apr 3, 2017
-- Latest Findings from Ongoing Collaboration with Memorial Sloan Kettering (MSK) Support Potential Applications for Combining CAR T and Anti-PS in Treatment of Solid Tumors -- TUSTIN, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving pa...
Mar 23, 2017
TUSTIN, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, today announced that four preclinical a...
Mar 13, 2017
-- Avid Revenue Guidance Increased to $60 - $65 Million for Full FY 2017 and Contracted Backlog of Future Business Currently at $70 Million -- -- Multiple Preclinical Studies Demonstrating Bavituximab's Ability to Enhance Activity of Immune Stimulating Therapies Accepted for Presentation at AACR --TUSTIN, Calif., March 13, 2017 (GLOBE NEWSWIRE...
Mar 9, 2017
TUSTIN, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Prefer...
Mar 6, 2017
TUSTIN, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report fina...
Feb 22, 2017
TUSTIN, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced that the company will attend and participate at two upcoming life sciences industry conferences.  From February 27 through March 2, 2017, the company will host a corpo...
Feb 9, 2017
TUSTIN, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced the publication of positi...
Dec 12, 2016
-- Avid Posts Record Revenue of $23.4 Million During Second Quarter FY 2017 with Contracted Backlog of Future Business Currently at $73 Million -- -- Beta-2 Glycoprotein-1 (β2GP1) Identified as a Biomarker that Correlates with Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab Combination Comp...
Dec 6, 2016
TUSTIN, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Prefe...
Dec 5, 2016
TUSTIN, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report finan...
Nov 14, 2016
-- Promising Results of MSK Study Evaluating Combinations of PS-Targeting Treatment, Anti-PD-1 and Radiation in Mouse B16 Melanoma Model Presented at SITC 2016 -- -- New Data from Second Study Conducted by Peregrine Shows Triple Combination of PS-Targeting Treatment, Anti-PD-1 and Anti-LAG3 Created Long-Term Immunity in Triple Negative Breast ...
Oct 24, 2016
-- Combination of PS-Targeting Antibody and Anti-PD-L1 Therapy, With or Without Chemotherapy, Led to Greater Anti-Tumor Activity Than Single Agent Treatment or Dual Combinations With Chemotherapy -- -- Additional Experiments Demonstrate that PS Expression is Upregulated on Cancer Cells Following Chemotherapy, Radiation or Photodynamic Therapy ...
Oct 10, 2016
-- Company Has Identified Beta-2 Glycoprotein-1 (β2GP1) as a Biomarker that Correlates with Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab Combination Compared to Chemotherapy Alone -- -- Ongoing SUNRISE Trial Biomarker Analysis Expected to Identify Additional Biomarkers Associated with Pa...
Sep 27, 2016
-- Complete Tumor Regression Seen in 80% of Animals Treated with Triple Combination of PS-Targeting Antibody, Anti-PD-1 Therapy and Anti-Lag3 Therapy vs. 0% of Animals Receiving Double Anti-PD-1/Anti-Lag3 Treatment Combination --   -- Triple Combination Shows Statistically Significant Increases in Key Tumor Fighting Immune Cells and a Reductio...
Sep 21, 2016
TUSTIN, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that top-line data from ...
Sep 8, 2016
--SUNRISE Top-line Data Accepted for Late-Breaking Oral Presentation at European Society of Medical Oncology Congress in October 2016 -- -- Avid First Quarter Revenue of $5.6 Million with Over $20 Million in Revenue Projected in Second Quarter  --             -- Company Reaffirms Revenue Projection of $50 - $55 Million for Full FY 2017 with G...
Sep 6, 2016
TUSTIN, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Prefer...
Sep 6, 2016
TUSTIN, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that the National Compre...
Sep 1, 2016
TUSTIN, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report fina...
Aug 9, 2016
TUSTIN, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced that the company will have a significant presence at Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit, being held August 15-19, 2016 in Bosto...
Jul 14, 2016
-- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 -- -- Growing Biomanufacturing Demand Prompts Plans for Third Manufacturing Facility Expected to be Commissioned by mid-2017 ---- Analysis of Data from SUNRISE Phase III Trial Ongoing with New Clinical Trials...
Jul 14, 2016
--New Technology Efficiently Builds on the Company's Existing Phosphatidylserine (PS) Targeting Platform and Assay Development Capabilities-- --Stand Alone Program That Offers Significant Value Creation Potential and Early Partnering Opportunities-- --New Technology to Also be Evaluated in Conjunction with Ongoing Bavituximab Clinical Dev...
Jul 7, 2016
TUSTIN, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by delivering high quality biological products through its contract development and manufacturing organization (CDMO) services and by advancing its novel R&D pipeline, tod...
Jun 2, 2016
TUSTIN, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Preferr...
Jun 2, 2016
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months - - Drug Development Strategy to Focus on Early Stage Clinical Trials of Bavitu...
Apr 20, 2016
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells - - Novel Genetic Analysis Technology Further Validates Immune Modulating Mechanism of Bavituximab and Anti-PD-1 Combination; Supports Clinical E...
Mar 9, 2016
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations-- --Full Fiscal Year 2016 Revenue From Biomanufacturing Business, Avid Bioservices, Expected to Top $40 Million-- --New State-of-the-Art Production Facility Commissioned and Ready for GMP Manufacturing Expand...
Mar 7, 2016
TUSTIN, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Prefer...
Mar 7, 2016
TUSTIN, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been forma...
Mar 3, 2016
TUSTIN, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 201...
Feb 25, 2016
TUSTIN, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it is discontinuing the company's Phase III SUNRISE trial of bavituximab in patients with previou...
Jan 20, 2016
TUSTIN, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that members of the company's scientific team will deliver podium presentations focused on the role of...
Jan 11, 2016
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 -- -- Phase II/III Study in HER2-Negative Metastatic Breast Cancer is Now Underway with a Second Phase II Study in Early Stage Triple Negative Breast Cancer to Begin in Q1 2016 -- -- Additional Studies t...
Jan 6, 2016
TUSTIN, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network® (NCCN®) to expa...
Dec 10, 2015
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial-- --Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New Clinical Trials Are Being Initiated-- --Peregrine Closes $20 Million Financing to Support Late-Stage Clinical Trials-- --Biomanufacturing Business, Avid Bios...
Dec 7, 2015
TUSTIN, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Preferr...
Dec 3, 2015
TUSTIN, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 201...
Nov 23, 2015
TUSTIN, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New ...
Nov 9, 2015
- Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone - - New Custom-Designed Immuno-Profiling Clinical Test Provides Further Evidence of Bavituxmab's Immune Modulating Mechanism of Action in the Tumor Mic...
Oct 15, 2015
TUSTIN, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to inclu...
Sep 9, 2015
--Peregrine and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial-- --Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015-- --Avid Bioservices Reports $9.4 Million in First Quarter Revenue-- TUSTIN, Calif., Sept. 09, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, I...
Sep 8, 2015
TUSTIN, Calif., Sept. 08, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Prefer...
Sep 8, 2015
TUSTIN, Calif., Sept. 08, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced positive new data from a translational study of bavituximab, the company's investigational phosphatid...
Sep 3, 2015
TUSTIN, Calif., Sept. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the first quarter of fiscal year 2016 ended July 31, 2015 o...
Aug 26, 2015
- Increasing Activated T Cells in Tumors Demonstrates Potential Complement to anti-PD-1 and anti-PD-L1 Checkpoint Inhibitors - - Clinical and Preclinical Studies Demonstrate Estimated Survival Curves that Plateau - TUSTIN, Calif., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceut...
Aug 24, 2015
TUSTIN, Calif., Aug. 24, 2015 (GLOBE NEWSWIRE) -- AstraZeneca (NYSE:AZN) and Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that they have entered into a cancer immunotherapy clinical trial collabora...
Jul 14, 2015
-- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015 - -- Initiation of Later-Stage Bavituximab Trials to Expand Commercial Potential in NSCLC and Breast Cancer Planned for Second Half of Calendar Year 2015 -- -- Avid's Contract Manufacturing Revenue Exceeds $26 Million for Fiscal Year 2015 - ...
Jul 7, 2015
TUSTIN, Calif., July 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing novel investigational products that help harness the body's own immune system to fight cancer, today announced that it will report financial results for the fourth quarter and fiscal yea...
Jun 25, 2015
-Bavituximab Patent Secured in Countries Across Europe- -Bavituximab Phase III Clinical Trial Underway at Over 150 Worldwide Clinical Sites Including Over 75 Sites in Eight European Countries- TUSTIN, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focu...
Jun 5, 2015
TUSTIN, Calif., June 5, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Preferr...
Jun 1, 2015
- New Data Show that Bavituximab Alone and in Combination with Docetaxel Elicits a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients - - PS-Targeting Antibodies Combined with Anti-PD-1 Reverses Tumor Immunosuppression and Activates Tumor Fighting CD8+ Immune Cells in Models of Melanoma and Breast Cancer -...
Jun 1, 2015
- Phase II Trial to Evaluate Combination of Bavituximab and Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer - - Phase II/III Combination Trial to Advance Bavituximab with Chemotherapy Combinations in HER2 Negative Breast Cancer - - New Studies Expected to be Underway as Phase III SUNRISE Trial in Lung Cancer Completes Enrollm...
May 29, 2015
TUSTIN, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, today announced that the company has entered into a sponsored research agreement with Me...
May 27, 2015
TUSTIN, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology (I-O) agent in Phase III development for the treatment of lung cancer, invites investors and the general public to listen to a webcast of its roundtable discus...
May 13, 2015
TUSTIN, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced the presentation of three posters at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting...
Apr 21, 2015
- Combination Treatment Reduces Tumor Immune System Blockade and Enhances Tumor Specific Immune Responses - - Studies Reveal Significant Increases in Tumor-Infiltrating CD8+ T Cells and Immune-Activating Cytokines while Decreasing Tumor-Promoting Macrophages and Myeloid Cells - TUSTIN, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- Per...
Apr 20, 2015
- Bavituximab Alone and in Combination with Docetaxel Elicit a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients - - Immune Modulating Results Consistent with Previously Conducted Translational Studies in Liver Cancer - - Presented Data Further Support Clinical Studies Evaluating the Effectiveness...
Apr 14, 2015
TUSTIN, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Phil...
Mar 31, 2015
- Combination of Bavituximab and Paclitaxel Achieved an 85% Objective Response- - Design of Phase II Clinical Trial Underway - TUSTIN, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP), today announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsore...
Mar 12, 2015
- SUNRISE Phase III Lung Cancer Trial On Track to Complete Enrollment by Calendar Year-End - - Encouraging and Consistent Data from Immuno-Oncology Development Program Continue to Support Bavituximab's Immunostimulatory Mechanism - - Avid Bioservices Increases Revenue Guidance to Between $23 and $25 Million for Full Fiscal Year 201...
Mar 10, 2015
TUSTIN, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Prefe...
Mar 5, 2015
TUSTIN, Calif., March 5, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced that it will report financial results for the third quarter fiscal year (FY) 2015 ended January 31, 2015...
Mar 2, 2015
TUSTIN, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clini...
Feb 9, 2015
TUSTIN, CA -- (Marketwired) -- 02/09/15 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation s...
Jan 16, 2015
TUSTIN, CA -- (Marketwired) -- 01/16/15 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology (ASCO) Gastr...
Dec 12, 2014
TUSTIN, CA -- (Marketwired) -- 12/12/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, today announced preclinical data from recently con...
Dec 10, 2014
TUSTIN, CA -- (Marketwired) -- 12/10/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, a new immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinica...
Dec 10, 2014
TUSTIN, CA -- (Marketwired) -- 12/10/14 -- Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the bi...
Dec 9, 2014
TUSTIN, CA -- (Marketwired) -- 12/09/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Pr...
Dec 3, 2014
TUSTIN, CA -- (Marketwired) -- 12/03/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter fiscal year (FY) 2015 ended October 31, 20...
Nov 10, 2014
TUSTIN, CA -- (Marketwired) -- 11/10/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the Society for Immunotherapy of Cance...
Nov 7, 2014
TUSTIN, CA -- (Marketwired) -- 11/07/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the first of four presentations of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab. Data from today's presenta...
Oct 30, 2014
TUSTIN, CA -- (Marketwired) -- 10/30/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of data from the Phase Ib investigator-sponsored trial (IST) of its immunotherapy bavituximab in combination with the chemotherapies pemetrexed and carboplatin in patients with previously untreated, locally...
Oct 15, 2014
TUSTIN, CA -- (Marketwired) -- 10/15/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the publication of a peer-reviewed manuscript related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody, exhibits specific and strong bin...
Oct 6, 2014
TUSTIN, CA -- (Marketwired) -- 10/06/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of preclinical data related to the company's immuno-oncology development program and its lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody. Data show that PS-targeting agents in...
Sep 9, 2014
TUSTIN, CA -- (Marketwired) -- 09/09/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2015 ended July 31, 2014 and provided an up...
Sep 8, 2014
TUSTIN, CA -- (Marketwired) -- 09/08/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E P...
Sep 2, 2014
TUSTIN, CA -- (Marketwired) -- 09/02/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter fiscal year (FY) 2015 ended July 31, 2014 on...
Aug 11, 2014
TUSTIN, CA -- (Marketwired) -- 08/11/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announces preclinical data further validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform. Results show that the combination of a PS-targeting antibody equivalent to bavi...
Jul 14, 2014
TUSTIN, CA -- (Marketwired) -- 07/14/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2014 ended April 3...
Jul 7, 2014
TUSTIN, CA -- (Marketwired) -- 07/07/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2014 e...
Jun 10, 2014
TUSTIN, CA -- (Marketwired) -- 06/10/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Pre...
Apr 23, 2014
TUSTIN, CA -- (Marketwired) -- 04/23/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy®), for the treatment of advanced melanoma. Bavituximab ...
Apr 9, 2014
TUSTIN, CA -- (Marketwired) -- 04/09/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced data from studies validating the immune-stimulatory mechanism of action of bavituximab and demonstrating that the combination of a preclinical phosphatidylserine (PS)-targeting antibody with the immune checkpoint inhibitors...
Apr 7, 2014
TUSTIN, CA -- (Marketwired) -- 04/07/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic...
Apr 1, 2014
TUSTIN, CA -- (Marketwired) -- 04/01/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Ann...
Mar 14, 2014
TUSTIN, CA -- (Marketwired) -- 03/14/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of an update to the ongoing Investigator-Sponsored Trial (IST) of its immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar®) in patients with advanced hepatocellular carcin...
Mar 13, 2014
TUSTIN, CA -- (Marketwired) -- 03/13/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine (PS)-targeting antibodies in both oncology and antivir...
Mar 11, 2014
TUSTIN, CA -- (Marketwired) -- 03/11/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The quarterly dividend on the Series E Preferred ...
Mar 11, 2014
TUSTIN, CA -- (Marketwired) -- 03/11/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-...
Mar 7, 2014
TUSTIN, CA -- (Marketwired) -- 03/07/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the third quarter of fiscal year (FY) 2014 ended January 31, 20...
Mar 4, 2014
TUSTIN, CA -- (Marketwired) -- 03/04/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the presentation of data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies at two upcoming Keystone Symposia to be held March 9-13, 2014....
Feb 27, 2014
TUSTIN, CA -- (Marketwired) -- 02/27/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the third quarter of fiscal year (FY) 2014 on March 7, 2...
Feb 27, 2014
TUSTIN, CA -- (Marketwired) -- 02/27/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), announced today that the underwriters of its underwritten public offering of its 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock") have partially exercised their option to cover overallotments and have purchased ...
Feb 19, 2014
TUSTIN, CA -- (Marketwired) -- 02/19/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that the company will participate in the following investor conferences: 2014 RBC Capital Markets' Glo...
Feb 19, 2014
TUSTIN, CA -- (Marketwired) -- 02/19/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (the "Company"), announced today that it has closed its previously announced underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock") at a public offering price of $25.00 per share. ...
Feb 11, 2014
TUSTIN, CA -- (Marketwired) -- 02/11/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (the "Company"), announced today that it has priced an underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock") at a public offering price of $25.00 per share. Holders of Series E Pr...
Feb 5, 2014
TUSTIN, CA -- (Marketwired) -- 02/05/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (the "Company"), announced today that it intends to offer and sell shares of its newly-designated 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"), in an underwritten public offering. In connection with the offering, the Company ...
Jan 6, 2014
TUSTIN, CA -- (Marketwired) -- 01/06/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that the company has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer (NSCLC). Recent...
Dec 30, 2013
TUSTIN, CA -- (Marketwired) -- 12/30/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States. SUNRISE is a pivotal Phase III clinical trial comparing the company's investigational immunotherapy bavituximab plus the chemotherapy docetaxe...
Dec 10, 2013
TUSTIN, CA -- (Marketwired) -- 12/10/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter of fiscal year (FY) 2014 ended October 31, 2013 and provided an update o...
Nov 26, 2013
TUSTIN, CA -- (Marketwired) -- 11/26/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the following upcoming events. Piper Jaffray 25th Annual Healthcare Conference Date: Tues...
Nov 8, 2013
TUSTIN, CA -- (Marketwired) -- 11/08/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the presentation of data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland being held November 7-10. The data showed that phosphatidylserine (PS)-targeting antibodies reactivate tumor immunity at m...
Nov 5, 2013
TUSTIN, CA -- (Marketwired) -- 11/05/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will present a company update at the Credit Suisse 20...
Oct 15, 2013
TUSTIN, CA -- (Marketwired) -- 10/15/13 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that participants at the International Association for the Study of Lung Cancer's (IALSC) 15th World Conference on Lung Cancer to be held October 27 - 30, 2013 in Sydney, Australia will discuss novel immunotherapy checkpoint inhibitors including ...
Sep 9, 2013
TUSTIN, CA -- (Marketwired) -- 09/09/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2014 ended July 31, 2013 and provided an update on it...
Sep 9, 2013
TUSTIN, CA -- (Marketwired) -- 09/09/13 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced the publication of preclinical research highlighting the immune-stimulatory mechanism of action of phosphatidylserine (PS)-targeting antibodies, such as the company's lead drug candidate bavituximab. The manuscript details the results from a seri...
Sep 3, 2013
TUSTIN, CA -- (Marketwired) -- 09/03/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter of fiscal year (FY) 2014 on September ...
Aug 14, 2013
TUSTIN, CA -- (Marketwired) -- 08/14/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the presentation of preclinical data and ongoing drug development activities highlighting the immune-stimulatory mechanism of action of phosphatidylserine (PS)-targeting antibodies, such as the company's lead drug candidate bavituximab. Dat...
Aug 6, 2013
TUSTIN, CA -- (Marketwired) -- 08/06/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that members of its management team will be presenting at the following conferences: Wedbush Securitie...
Jul 11, 2013
TUSTIN, CA -- (Marketwired) -- 07/11/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and fiscal year (FY) ended April 30, 2013 and provided an update on its ...
Jul 2, 2013
TUSTIN, CA -- (Marketwired) -- 07/02/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2013 on July 11,...
Jun 27, 2013
TUSTIN, CA -- (Marketwired) -- 06/27/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today provided an update on its bavituximab oncology program including financing activities focused on advancing its lead program into a pivotal Phase III trial and adapting its clinical development plan in accordance with the recent increased understandin...
Jun 24, 2013
TUSTIN, CA -- (Marketwired) -- 06/24/13 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received notification it will join the Russell 3000® and Russell Global Indexes when Russell Investments reconstitutes its family of U.S. indexes on June 28, 2013, according to a list of additions posted on June 21, 2013. ...
Jun 3, 2013
TUSTIN, CA -- (Marketwired) -- 06/03/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported today that data was presented at the 2013 ASCO Annual Meeting from two clinical trials evaluating the company's lead clinical candidate bavituximab. In the first study presented, interim data from a Phase I trial evaluating bavituximab plus paclit...
Jun 3, 2013
TUSTIN, CA -- (Marketwired) -- 06/03/13 -- Peregrine Pharmaceuticals (NASDAQ: PPHM), today reported final data from its randomized, double-blind, placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer (NSCLC). Final results from the Phase II trial showed an improvement in median overall survival...
May 20, 2013
TUSTIN, CA -- (Marketwired) -- 05/20/13 -- Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase III registration trial design...
May 16, 2013
TUSTIN, CA -- (Marketwired) -- 05/16/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the presentation of three clinical posters at the 2013 American Society of Clinical Oncology (ASCO) Annual Meetin...
Apr 29, 2013
TUSTIN, CA--(Marketwired - Apr 29, 2013) - Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the completion of patient enrollment in an i...
Apr 10, 2013
TUSTIN, CA -- (Marketwired) -- 04/10/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today highlighted data presented at the Annual Meeting of the American Association for Cancer Research (AACR). Data was presented...
Apr 1, 2013
TUSTIN, CA -- (Marketwire) -- 04/01/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 104th Annual Meeting of th...
Mar 12, 2013
TUSTIN, CA -- (Marketwire) -- 03/12/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the third quarter ended January 31, 2013 of fiscal year (FY) 2013 and provided an update on ...
Mar 5, 2013
TUSTIN, CA -- (Marketwire) -- 03/05/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the third quarter of the fiscal year (FY) 2013 on March 1...
Feb 26, 2013
TUSTIN, CA -- (Marketwire) -- 02/26/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will participate at the following investor conferences...
Feb 26, 2013
TUSTIN, CA and HUNTINGTON BEACH, CA -- (Marketwire) -- 02/26/13 -- Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will present two posters at IBC's Biopharmaceutical Development & Production Conference to be held in Huntington Beach, California, February 26 - March 1, 2013. Avid w...
Feb 19, 2013
TUSTIN, CA -- (Marketwire) -- 02/19/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today reported data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial has been updated based on completion of an earlier review of discrep...
Feb 13, 2013
TUSTIN, CA -- (Marketwire) -- 02/13/13 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced results from its 70 patient open-label, randomized Phase II clinical trial of bavituximab used in combination with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer. The trial included the enrollment of patient...
Jan 7, 2013
TUSTIN, CA -- (Marketwire) -- 01/07/13 -- Peregrine Pharmaceuticals, Inc.(NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled tr...
Dec 11, 2012
TUSTIN, CA -- (Marketwire) -- 12/11/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement. The letter received today no...
Dec 10, 2012
TUSTIN, CA -- (Marketwire) -- 12/10/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on...
Dec 5, 2012
TUSTIN, CA -- (Marketwire) -- 12/05/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has made significant progress in advancing its Cotara program into late-stage development through its agreement ...
Dec 3, 2012
TUSTIN, CA -- (Marketwire) -- 12/03/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter of the fiscal year 2013 on December 10, 2012...
Nov 14, 2012
TUSTIN, CA -- (Marketwire) -- 11/14/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, announced that it received today a notice from The NASDAQ Stock Market indicating that the company's minimum bid price has fallen below ...
Oct 31, 2012
TUSTIN, CA -- (Marketwire) -- 10/31/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the presentation of preclinical data showing specific localization and enhancement of anti-tumor functions of immune cel...
Oct 17, 2012
TUSTIN, CA -- (Marketwire) -- 10/17/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided a company update on financing activities, its contract manufacturing business and upcoming potential clinical milestones....
Sep 27, 2012
TUSTIN, CA -- (Marketwire) -- 09/27/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has changed the location of its Annual Meeting of Stockholders to be held on October 18, 2012 at 10:00 am ...
Sep 24, 2012
TUSTIN, CA -- (Marketwire) -- 09/24/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) announced today that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell...
Sep 12, 2012
TUSTIN, CA -- (Marketwire) -- 09/12/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that its management team will be meeting with investors to review its portfolio of novel drug candidates and the recent positive clinical data from the company's Phase II trial in second-line non-small cell lung cancer, as part of the 3rd An...
Sep 10, 2012
TUSTIN, CA -- (Marketwire) -- 09/10/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the first quarter ended July 31, 2012 of fiscal year (FY) 2013 and provided an update on its...
Sep 7, 2012
TUSTIN, CA -- (Marketwire) -- 09/07/12 -- Interim Data from Double-Blind, Placebo-Controlled Trial Presented at Late-Breaking Plenary Session at Leading Oncology Symposium Data Show Statistically Significant Improvement in Overall Survival for Patients Receiving Bavituximab Plus Docetaxel Versus Docetaxel Alone Clinical...
Sep 4, 2012
TUSTIN, CA -- (Marketwire) -- 09/04/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter of the fiscal year 2013 on September 10...
Sep 4, 2012
TUSTIN, CA -- (Marketwire) -- 09/04/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced it will be presenting data from its double-blind, placebo controlled, Phase II bavituximab trial in...
Aug 30, 2012
TUSTIN, CA -- (Marketwire) -- 08/30/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that it has secured a $30 million term loan from Oxford Finance, which was the lead lender, MidCap Financial, and Silicon Valley Bank. Under the loan facility, the company received initial funding of $15 million and has an option to receive ...
Aug 29, 2012
TUSTIN, CA -- (Marketwire) -- 08/29/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the 2012 Stifel Nicolaus Heal...
Aug 8, 2012
TUSTIN, CA -- (Marketwire) -- 08/08/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the Wedbush Securities Life S...
Jul 30, 2012
TUSTIN, CA -- (Marketwire) -- 07/30/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement, as a result of the closing bid price of its...
Jul 16, 2012
TUSTIN, CA -- (Marketwire) -- 07/16/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the diagnosis and treatment of cancer and infectious diseases, today announced financial results for the fourth quarter and fiscal year (FY) 2012 ended April 30,...
Jul 16, 2012
TUSTIN, CA and DALLAS, TX -- (Marketwire) -- 07/16/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the diagnosis and treatment of cancer and viral infections, today announced the initiation of an investigator-sponsored trial (IST) for patients w...
Jul 9, 2012
TUSTIN, CA -- (Marketwire) -- 07/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it will report financial results for the fourth quarter and fiscal year 2012...
Jul 5, 2012
TUSTIN, CA -- (Marketwire) -- 07/05/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that Steven King, president and chief executive officer, will present at the 2012...
Jun 25, 2012
TUSTIN, CA -- (Marketwire) -- 06/25/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the completion of enrollment and randomization of 70 patients in a Phase II trial evaluating bavituximab in combination with gemcitabine versus gemcitabine alone in patients with previously untreated stage IV pancreatic cancer. Peregrine's l...
Jun 11, 2012
TUSTIN, CA -- (MARKETWIRE) -- 06/11/12 -- Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will collaborate with San Diego-based Phage Pharmaceuticals, whereby Avid will add a custom protein production service using Phage's novel bacteriophage production system to its suite of current cli...
May 21, 2012
TUSTIN, CA -- (Marketwire) -- 05/21/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase IIb trial evaluating two dose levels of bavituximab plus docetaxel versus docetaxel plus placebo (control arm) in patients with second-line non-small cell...
May 10, 2012
TUSTIN, CA -- (Marketwire) -- 05/10/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that researchers have highlighted promising preclinical data at the 2012 Annual Me...
Apr 26, 2012
TUSTIN, CA -- (Marketwire) -- 04/26/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that its phosphatidylserine (PS)-targeting technology platform and its lead drug candidate, bavituximab, will be highlighted at a symposium hosted by The New York Academy of Sciences. The event entitled "Phosphatidylserine Asymmetry and Cel...
Apr 4, 2012
TUSTIN, CA -- (Marketwire) -- 04/04/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today highlighted positive data from two Phase I investigator-sponsored trials (IST) and one precl...
Apr 3, 2012
TUSTIN, CA -- (Marketwire) -- 04/03/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it has launched a program for its experimental phosphatidylserine (PS)-target...
Apr 2, 2012
TUSTIN, CA -- (Marketwire) -- 04/02/12 -- Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today presented data at the Annual Meeting of the American Association of Cancer Research (AACR), demonstrating its ability to make genetic modifications to monoclonal antibodies, resulting in enhanced Fc related function...
Apr 2, 2012
TUSTIN, CA -- (Marketwire) -- 04/02/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today highlighted data(1) presented at the Annual Meeting of the American Association for Cancer Research (AACR...
Mar 28, 2012
TUSTIN, CA -- (Marketwire) -- 03/28/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, announced that it received today a notice from The NASDAQ Stock Market indicating that the company's minimum bid...
Mar 9, 2012
TUSTIN, CA -- (MARKET WIRE) -- 03/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced financial results for the third quarter ended January 31, 2012 of fiscal year (FY) 2012 and pr...
Mar 9, 2012
TUSTIN, CA -- (MARKET WIRE) -- 03/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced top-line overall response rate (ORR) and current median progression free survival (PFS) estimates from its phase II trial comparing bavituximab plus carboplatin and paclitaxel versus carboplatin and paclitaxel alone in patients with front-l...
Mar 1, 2012
TUSTIN, CA -- (MARKET WIRE) -- 03/01/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the third quarter of the fiscal year 2012 on March 9, 2...
Mar 1, 2012
TUSTIN, CA -- (MARKET WIRE) -- 03/01/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that data from seven clinical and preclinical studies investigating the company's lead clinica...
Feb 27, 2012
TUSTIN, CA -- (MARKET WIRE) -- 02/27/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the following two investor conferences in...
Feb 23, 2012
TUSTIN, CA and SAN DIEGO, CA -- (MARKET WIRE) -- 02/23/12 -- Avid Bioservices, Inc., a leading provider of integrated biomanufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will present two posters at IBC's 28th International Antibody Development & Production Conference to be held ...
Feb 9, 2012
TUSTIN, CA -- (MARKET WIRE) -- 02/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, its president and chief executive officer, is scheduled to present at the 14...
Dec 29, 2011
TUSTIN, CA -- (MARKET WIRE) -- 12/29/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chro...
Dec 12, 2011
TUSTIN, CA -- (MARKET WIRE) -- 12/12/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2011 of fiscal year (FY) 2012 and prov...
Dec 6, 2011
TUSTIN, CA -- (MARKET WIRE) -- 12/06/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced preliminary results from a randomized Phase II trial showing a 50% improvement in overall tumor response rates (ORR) in non-small cell lung cancer (NSCLC) patients. Patients treated with bavituximab plus carboplatin and paclitaxel currentl...
Dec 5, 2011
TUSTIN, CA -- (MARKET WIRE) -- 12/05/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the second quarter of the fiscal year 2012 on December ...
Nov 22, 2011
TUSTIN, CA -- (MARKET WIRE) -- 11/22/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 23.2 month median overall survival (OS) from a single-arm Phase II trial evaluating bavituximab i...
Nov 8, 2011
TUSTIN, CA -- (MARKET WIRE) -- 11/08/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 8th Annual Lazard Capital Markets Healthcare Conference in New York, NY on...
Oct 6, 2011
TUSTIN, CA -- (MARKET WIRE) -- 10/06/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment and randomization of 121 patients in a double-blind, placebo-control...
Sep 26, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/26/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has completed patient enrollment in its second randomized Phase II clinical trial for bav...
Sep 20, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/20/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 2011 JMP Securities Healthcare Conference in New York, NY on Tuesday, Sept...
Sep 12, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/12/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that new data from its phosphatidylserine (PS)-targeting tumor imaging studies were presented at ...
Sep 9, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/09/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the first quarter of fiscal year (FY) 2012 ended July 31, 2011 and provided...
Sep 8, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/08/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment and randomization of 86 patients with previously untreated non-small...
Sep 2, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/02/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter of fiscal year 2012 on September 9, 20...
Sep 2, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/02/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has entered into subscription agreements for the sale of an aggregate of 6,252,252 shares...
Sep 1, 2011
TUSTIN, CA -- (MARKET WIRE) -- 09/01/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 2011 Stifel Nicolaus Healthcare Conference in Boston, Massachusetts on Thu...
Aug 24, 2011
TUSTIN, CA -- (MARKET WIRE) -- 08/24/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 20.7 month median overall survival (OS) from a prior single-arm Phase II trial evaluating bavitux...
Jul 14, 2011
TUSTIN, CA -- (MARKET WIRE) -- 07/14/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the fourth quarter and fiscal year (FY) 2011 ended April 30, 201...
Jul 7, 2011
TUSTIN, CA -- (MARKET WIRE) -- 07/07/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the fourth quarter and fiscal year 2011 on July 14, 201...
Jun 15, 2011
TUSTIN, CA -- (MARKET WIRE) -- 06/15/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today reported promising median overall survival (MOS) of 12.4 months from a Phase II clinical trial evaluating b...
Jun 3, 2011
TUSTIN, CA and CHICAGO, IL -- (MARKET WIRE) -- 06/03/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today is presenting data from a Phase II trial of Cotara® in recurrent glioblastoma multifor...
May 31, 2011
TUSTIN, CA -- (MARKET WIRE) -- 05/31/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the appointment of Jeffrey L. Masten as Vice President, Quality. In this newly created position, ...
May 26, 2011
TUSTIN, CA and BARCELONA, SPAIN -- (MARKET WIRE) -- 05/26/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced a keynote presentation at the 10th Annual Informa Life Sciences Recombinant ...
May 25, 2011
TUSTIN, CA and IRVINE, CA -- (MARKET WIRE) -- 05/25/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the initiation of an investigator-sponsored trial (IST) for patients with castrati...
May 19, 2011
TUSTIN, CA -- (MARKET WIRE) -- 05/19/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced interim median overall survival of 8.8 months (38 weeks, 40 patients at first relapse) from a Pha...
Apr 6, 2011
TUSTIN, CA and ORLANDO, FL -- (MARKET WIRE) -- 04/06/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, highlighted data presented at the Annual Meeting of the American Association of Cancer Research (...
Apr 5, 2011
TUSTIN, CA and ORLANDO, FL -- (MARKET WIRE) -- 04/05/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that its phosphatidylserine (PS)-targeting antibody significantly enhanced the an...
Apr 4, 2011
TUSTIN, CA, and BERLIN, GERMANY -- (MARKET WIRE) -- 04/04/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced data from its Phase Ib dose escalation safety study of bavituximab in patien...
Mar 11, 2011
TUSTIN, CA -- (MARKET WIRE) -- 03/11/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the third quarter ended January 31, 2011 for its fiscal year (FY...
Mar 10, 2011
TUSTIN, CA -- (MARKET WIRE) -- 03/10/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference in Laguna Nigu...
Mar 9, 2011
TUSTIN, CA -- (MARKET WIRE) -- 03/09/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the appointment of Kerstin B. Menander, M.D., Ph.D. as head of medical oncology. During Dr. Menan...
Mar 8, 2011
TUSTIN, CA and CHAPEL HILL, NC -- (MARKET WIRE) -- 03/08/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the initiation of an investigator-sponsored trial (IST) for patients with che...
Mar 7, 2011
TUSTIN, CA -- (MARKET WIRE) -- 03/07/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from the company's Phase Ib dose escalation safety study of bavituximab in patients coi...
Mar 4, 2011
TUSTIN, CA -- (MARKET WIRE) -- 03/04/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the third quarter fiscal year 2011 on March 11, 2011 af...
Feb 28, 2011
TUSTIN, CA -- (MARKET WIRE) -- 02/28/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four studies investigating the company's lead phosphatidylserine (PS)-targeting cl...
Jan 31, 2011
TUSTIN, CA -- (MARKET WIRE) -- 01/31/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment in the company's Phase Ib dose escalation safety study of bavituxima...
Jan 19, 2011
TUSTIN, CA, and TUCSON, AZ -- (MARKET WIRE) -- 01/19/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the initiation of an investigator-sponsored trial (IST) for patients with HER2-ne...
Jan 10, 2011
TUSTIN, CA -- (MARKET WIRE) -- 01/10/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated ...
Jan 5, 2011
TUSTIN, CA -- (MARKET WIRE) -- 01/05/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated ...
Dec 20, 2010
TUSTIN, CA -- (MARKET WIRE) -- 12/20/10 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment in the company's Phase II dose confirmation trial of Cotara® in pati...
Dec 9, 2010
TUSTIN, CA -- (MARKET WIRE) -- 12/09/10 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2010 for its fiscal year (F...
Dec 8, 2010
TUSTIN, CA, December 8, 2010 -- Avid Bioservices, Inc., a leading provider of integrated biomanufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced an agreement to provide services for a privately held U.S. and China-based biopharmaceutical company focused on developing biosimilars for global ...
Dec 2, 2010
TUSTIN, CA -- (MARKET WIRE) -- 12/02/10 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the second quarter fiscal year 2011 on December 9, 2010...
Dec 1, 2010
TUSTIN, CA and DALLAS, TX -- (MARKET WIRE) -- 12/01/10 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the initiation of an investigator-sponsored trial (IST) for patients with advanced...
Nov 17, 2010
TUSTIN, CA, and ORLANDO, FL -- (MARKET WIRE) -- 11/17/10 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced preclinical data demonstrating its lead antibody bavituximab's ability to bind t...
Nov 2, 2010
TUSTIN, CA, Nov 02, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the award of $977,917 under the Internal Revenue Service's Section 48D for Quali...
Oct 25, 2010
TUSTIN, CA and BOSTON, MA, Oct 25, 2010 (MARKETWIRE via COMTEX News Network) -- Avid Bioservices, Inc., a leading provider of integrated commercial and clinical manufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc., announced that company representatives will present at IBC's Preclinical Scale Bioprocessing Conference, Strategi...
Oct 21, 2010
TUSTIN, CA, Oct 21, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the appointment of Carlton M. Johnson as chairman of the board of directors. Mr....
Oct 20, 2010
TUSTIN, CA, Oct 20, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from a preclinical study of bavituximab have been accepted for present...
Oct 18, 2010
TUSTIN, CA and SAN FRANCISCO, CA, Oct 18, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today reported interim data from an ongoing Phase II clinical trial of its...
Oct 6, 2010
TUSTIN, CA, Oct 06, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the upcoming presentation of interim data from an ongoing Phase II clinical tria...
Sep 30, 2010
TUSTIN, CA and COPENHAGEN, DENMARK and OSLO, NORWAY, Sep 30, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company, and Affitech A/S (COPN: AFFI), the antibody medicines company, today announced that the companies have agreed to amend certain terms of their worldwide ...
Sep 20, 2010
TUSTIN, CA, Sep 20, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update on its government contract with the Transformational Medical Technologi...
Sep 9, 2010
TUSTIN, CA, Sep 09, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced its clinical progress and financial results for the first quarter ended July 31,...
Sep 8, 2010
TUSTIN, CA, Sep 08, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the Rodman & Renshaw 12th Annual Healthcare Conference on Monday,...
Sep 7, 2010
TUSTIN, CA, Sep 07, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the issuance of two U.S. patents providing protection for tumor vasculature imag...
Sep 2, 2010
TUSTIN, CA, Sep 02, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter fiscal year 2011 on ...
Jul 14, 2010
TUSTIN, CA, Jul 14, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the fourth quarter and fiscal year (FY) 2010 ended April 3...
Jul 14, 2010
TUSTIN, CA, Jul 14, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a second randomized Phase IIb non-small cell lung cancer (...
Jun 30, 2010
TUSTIN, CA, Jun 30, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the fourth quarter and fiscal year 201...
Jun 28, 2010
TUSTIN, CA, Jun 28, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that on June 25, 2010 it was added to the Russell 3000(R) Index following the Ru...
Jun 28, 2010
TUSTIN, CA, Jun 28, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update on its government-sponsored research programs. Under its first governme...
Jun 14, 2010
TUSTIN, CA, Jun 14, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, is set to join the broad-market Russell 3000(R) Index when Russell Investments reconstitutes its...
Jun 9, 2010
TUSTIN, CA, Jun 09, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today will present tumor response and progression-free survival data from three clinical Phase II tr...
Jun 4, 2010
TUSTIN, CA, Jun 04, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced positive data from a Phase II clinical trial treating front-line non-small cell lung...
Jun 3, 2010
TUSTIN, CA, Jun 03, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced data to be presented on June 6, 2010 at the ASCO Annual Meeting from a Phase I trial...
Jun 2, 2010
TUSTIN, CA, Jun 02, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at Needham & Company's Ninth Annual Healthcare Conference on Wednesd...
May 28, 2010
TUSTIN, CA, May 28, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced new median progression-free survival (PFS) data of 7.4 months from a Phase II trial ...
May 27, 2010
TUSTIN, CA, May 27, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced positive objective tumor response and median progression-free survival (PFS) data fr...
May 20, 2010
TUSTIN, CA, May 20, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that it will present cancer data from four clinical trials, including its first-in-class phosphatidylserine (PS)-targeting monoclonal antibody bavituximab and novel brain cancer therapy Cotara, at the 2010 ASCO Annual Meet...
May 10, 2010
TUSTIN, CA, May 10, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the Rodman & Renshaw Sixth Annual Global Investment Conference in...
May 3, 2010
TUSTIN, CA and CHICAGO, IL, May 03, 2010 (MARKETWIRE via COMTEX News Network) -- Avid Bioservices, Inc., a leading provider of integrated commercial manufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced its participation in the 2010 BIO International Convention. -- Tuesday, May 4 through T...
May 3, 2010
TUSTIN, CA and IRVINE, CA, May 03, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, and Stason Pharmaceuticals, a privately-held U.S.-based pharmaceutical company commer...
Apr 21, 2010
WASHINGTON, DC and TUSTIN, CA, Apr 21, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced three data presentations at the AACR 101st Annual Meeting 2010 de...
Apr 19, 2010
WASHINGTON, D.C. and TUSTIN, CA, Apr 19, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today reported data from a new preclinical study demonstrating that the company...
Apr 15, 2010
TUSTIN, CA, Apr 15, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the publication of new data highlighting the tumor-killing potential of its lead phosphatidylserine (PS)-targeting antibody bavituximab in combination with an agent that induces apoptosis, or programmed cell death. In this...
Apr 13, 2010
TUSTIN, CA, Apr 13, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical stage biopharmaceutical company developing novel monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four clinical studies of bavituximab and Cotara(R) have been accepted for ...
Apr 12, 2010
TUSTIN, CA, Apr 12, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class phosphatidylserine (PS)-targeting monoclonal antibodies for the treatment of cancer and viral infections, today announced the launch of an investigator-sponsored trial ...
Apr 5, 2010
TUSTIN, Calif., April 5, 2010 -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing...
Apr 5, 2010
TUSTIN, Calif., April 5, 2010 -- Avid Bioservices, Inc., a wholly-owned subsidiary of Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that it has expanded its commercial supply relationship with Halozyme Therapeutics, Inc. with new manufacturing agreements. The companies have also entered into a long-term strategic rela...
Mar 31, 2010
TUSTIN, Calif., March 31, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been ac...
Mar 11, 2010
TUSTIN, Calif., March 11, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended...
Mar 5, 2010
TUSTIN, Calif., March 5, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the third quarter of fiscal year 2010 on March 11, 2010 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same ...
Mar 1, 2010
TUSTIN, Calif., March 1, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the following upcoming investor conferences: Peregrine will present at the Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010 at 3:15 pm EST. The con...
Feb 11, 2010
TUSTIN, Calif., Feb 11, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara(R) for the treatment of patients with gliobl...
Feb 2, 2010
TUSTIN, Calif., Feb 02, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 3:30 pm EST. The conference will be held at the Waldorf-Astoria Hotel in New York City. A live webc...
Jan 11, 2010
TUSTIN, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) today announced that Marvin R. Garovoy, MD, has joined the company as head of clinical science. Dr. Garovoy has extensive biotechnology industry experience in the design and conduct of clinical trials for innovative new drugs. At Pe...
Jan 6, 2010
TUSTIN, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the OneMedForum 2010 Finance Conference on January 13, 2010 at 2:00 p.m. PST. The conference will be held at the Sir Francis Drake Hotel in San Francisco. A live audio webcast ...
Dec 10, 2009
TUSTIN, Calif., Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the second quarter of fiscal year (FY) 2010 ended October 31, 2009. Total revenue for the second quarter of FY 2010 increased 255% to $6,896,000, compared to $1,941,000 for the comparab...
Dec 3, 2009
TUSTIN, Calif., Dec 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST...
Dec 2, 2009
TUSTIN, Calif., Dec 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara(R) in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoc...
Nov 18, 2009
TUSTIN, Calif., Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that researchers presented positive data on progress in its federally funded preclinical viral hemorrhagic fever (VHF) program, confirming that its phosphatidylserine (PS)-targeting antibodies bind to VHF vir...
Nov 10, 2009
TUSTIN, Calif., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with rad...
Nov 4, 2009
Nov 3, 2009
Oct 21, 2009
TUSTIN, Calif., Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Ph...
Oct 19, 2009
TUSTIN, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that Dr. Robert Garnick has joined the company as the head of regulatory affairs. Dr. Garnick was formerly the senior vice president of regulatory, quality and compliance at Genentech. During his 24-year c...
Oct 19, 2009
TUSTIN, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the previously announced 1-for-5 reverse stock split of the Company's common stock will become effective at 9:30 a.m. EDT today. Peregrine's shares will continue to trade on the NASDAQ Capital Market un...
Oct 16, 2009
TUSTIN, Calif., Oct 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that a previously approved reverse split of its common stock will take effect at the start of NASDAQ trading on Monday, October 19, 2009 on a 1-for-5 split-adjusted basis. Peregrine's shares will continue to...
Oct 7, 2009
TUSTIN, Calif., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has established a new Anti-Viral Research Group in its R&D organization. The new group has responsibility for coordinating, expanding and leveraging the company's multiple external collaborations alr...
Oct 5, 2009
TUSTIN, Calif., Oct 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the i...
Sep 21, 2009
TUSTIN, Calif., Sept 21, 2009 /PRNewswire via COMTEX News Network/ -- Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, and Boehringer Ingelheim, a global leader in biopharmaceutical development and manufacturing, today announced that the two companies have entered into a global strategic...
Sep 8, 2009
TUSTIN, Calif., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients. The trial's planned total of 46 patients has b...
Sep 3, 2009
TUSTIN, Calif., Sept 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable ...
Sep 2, 2009
BOSTON, Mass. and TUSTIN, Calif., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patie...
Sep 1, 2009
TUSTIN, Calif., Sept 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 10:25 am EDT. The conference will be held at the New York Palace Hotel in New...
Aug 31, 2009
TUSTIN, Calif., Aug 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the clinical d...
Aug 28, 2009
TUSTIN, Calif., August 28, 2009 – Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, today announced that it has further strengthened its executive team with the appointments of Truc Le as chief operating officer and Christopher Eso as vice president of business ...
Aug 27, 2009
TUSTIN, Calif., Aug 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year 2010 on September 3, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT ...
Aug 26, 2009
TUSTIN, Calif., Aug 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research ...
Jul 23, 2009
TUSTIN, Calif., July 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 at 8:30 am EDT at the Boca Raton Resort & Club in Florida. More information...
Jul 22, 2009
TUSTIN, Calif. and HORSHOLM, Denmark, July 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) and Affitech A/S (Nasdaq OMX: AFFI) today announced that they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF (Vascular Endothelial Growt...
Jul 14, 2009
TUSTIN, Calif., July 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced financial results for the fourth quarter and fiscal year (FY) 2009 ended April 30, 2009. Total revenues for the fourth quarter of FY 2009 increased to $7,867,000, compared to $901,000 for the comparable qu...
Jul 2, 2009
TUSTIN, Calif., July 2, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its fourth quarter and fiscal year 2009 financial results on July 14, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the sam...
Jul 1, 2009
TUSTIN, Calif., July 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which is known as In-Line labeli...
Jun 30, 2009
TUSTIN, Calif., June 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed the planned patient enrollment in its U.S. Phase I clinical trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. In a presentation of preliminary d...
Jun 24, 2009
TUSTIN, Calif., June 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported the issuance of a U.S. patent with broad claims covering vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent represents the first broad coverage of imaging claims under...
Jun 16, 2009
TORONTO and TUSTIN, Calif., June 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal radiation...
Jun 10, 2009
TUSTIN, Calif., June 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the ASCO Research Foundation has awarded one of its 2009 Career Development Awards to David Gerber, MD, of the University of Texas Southwestern Medical Center for a study of the biologic effects of bavi...
Jun 3, 2009
TUSTIN, Calif., June 3, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a monoclonal antibody with a uni...
Jun 1, 2009
ORLANDO, Fla. and TUSTIN, Calif., June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that preliminary results from a Phase II trial of its lead anti-phosphatidylserine antibody bavituximab in combination with docetaxel in patients with advanced breast cancer will be discusse...
May 28, 2009
TUSTIN, Calif., May 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today provided an update on progress in the company's clinical program for Cotara(R), a t...
May 27, 2009
TUSTIN, Calif., May 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that data from two ongoing clinical trials assessing its lead compound bav...
May 19, 2009
TUSTIN, Calif. and ATLANTA, GA, May 19, 2009 -- Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, today announced that senior vice president Richard Richieri will give a presentation at the 2009 BIO International Convention highlighting the key role contract manufa...
May 13, 2009
TUSTIN, Calif. and ATLANTA, GA, May 13, 2009 -- Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, today announced that its activities at the 2009 BIO International Convention will include a discussion by Avid’s senior vice president Richard Richieri on the ke...
May 4, 2009
TUSTIN, Calif., May 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment in its Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. The planned 46 patients have been enrolled and are currently und...
Apr 27, 2009
TUSTIN, Calif., April 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that updated preliminary data from its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer showed that nine of 14 evaluable patients in the initia...
Apr 22, 2009
DENVER and TUSTIN, Calif., April 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that preclinical data presented during the AACR 100th Annual...
Apr 21, 2009
DENVER and TUSTIN, Calif., April 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th ...
Apr 20, 2009
TUSTIN, Calif., April 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that updated preliminary data from the initial cohort of 21 patients in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel showed that 11 of 17 evaluable patients with...
Mar 31, 2009
TUSTIN, Calif., March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported the issuance of a U.S. patent that further strengthens the company's intellectual property leadership in the field of phospholipid-targeting agents for the treatment of life-threatening diseases. The new pa...
Mar 25, 2009
TUSTIN, Calif., March 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has received a letter from NASDAQ that provides Peregrine with an additional three months to regain compliance with the minimum bid price rule. Peregrine now has until October 26, 2009 to regain co...
Mar 12, 2009
TUSTIN, Calif., March 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the third quarter of fiscal year (FY) 2009 ended January 31, 2009. Total revenues for the current quarter increased 308% to $6,826,000, compared to $1,675,000 for the comparable qu...
Mar 9, 2009
TUSTIN, Calif., March 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 9:30 am EDT at the Boston Marriott Copley Place. A live webcast and archived r...
Mar 5, 2009
TUSTIN, Calif., March 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the third quarter of fiscal year 2009 on March 12, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on...
Feb 13, 2009
TUSTIN and SAN DIEGO, Calif., Feb 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Avid Bioservices, Inc. today reported that it presented data from several antibody projects using the company's recently installed Single-Use Bioreactors (S.U.B.) at the Thermo Scientific BioProduction Optimization Workshop held this week in San Diego, ...
Feb 11, 2009
TUSTIN, Calif., Feb 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the pre-specified Stage A primary endpoint in an ongoing Phase II clinical trial in patients with advanced breast cancer. The Phase II trial is an open-lab...
Feb 4, 2009
TUSTIN, Calif., Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- -Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the primary efficacy endpoint i...
Dec 24, 2008
TUSTIN, Calif., Dec 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious viral infections, today announced it has received a letter from NASDAQ that provides Peregrine with an ...
Dec 11, 2008
TUSTIN, Calif., Dec 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that Thomas A. Waltz, M.D., chairman of its Board of Directors, unexpectedly passed away on Wednesday. Dr. Waltz had been a director of Peregrine since 2004 and was chairman since 2005. At the time of his d...
Dec 10, 2008
TUSTIN, Calif., Dec 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- - Three Bavituximab Phase II Cancer Trials and the Company's Other Clinical Programs All Advanced During the Quarter - - Significant Validation Achieved for Bavituximab and Peregrine's Anti-PS Anti-Viral Platform in Nature Medicine Publication - - Company Enters into L...
Dec 10, 2008
TUSTIN, Calif., Dec 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has entered into a loan agreement for up to $10 million in proceeds. The initial funding of $5 million is expected to close within the next 10 days. The loan agreement includes an option to acquire ...
Dec 4, 2008
TUSTIN, Calif., Dec 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the second quarter of fiscal year 2009 on December 10, 2008 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST...
Nov 25, 2008
TUSTIN, Calif., Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of serious viral infections and cancer, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Numb...
Nov 24, 2008
TUSTIN, Calif., Nov 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- --PS-Targeting Antibodies May Represent a Completely New Class of Drugs with Broad Potential to Treat Life-Threatening Viral Infections-- --Peregrine's Clinical-Stage Anti-PS Agent Bavituximab and Equivalent Antibodies Cured Lethal Viral Infections in Preclinical Models...
Nov 10, 2008
TUSTIN, Calif., Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Avid Bioservices, Inc. today announced that it is expanding its biomanufacturing capabilities with the installation of two Thermo Scientific HyClone Single-Use Bioreactors (S.U.B.) in Avid's facility in Tustin, California. These innovative systems will further enhance Av...
Nov 5, 2008
TUSTIN, Calif., Nov 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 2:00 pm ET. The conference will be held at the New York Palace Hotel in New York ...
Oct 28, 2008
TUSTIN, Calif., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that senior management will present at the BIO Investor Forum 2008 on Thu...
Oct 27, 2008
TUSTIN, Calif., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Avid Bioservices, Inc. today announced it has signed a manufacturing supply agreement with Catalyst Biosciences, Inc. to produce clinical-grade material in support of their clinical candidate, CB 813, an improved version of factor VIIa for the treatment of acute bleeding...
Oct 23, 2008
TUSTIN, Calif., Oct 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that it has received a letter from NASDAQ that provides Peregrine with ad...
Oct 21, 2008
TUSTIN, Calif., Oct 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today announced that updated preliminary data from the first stage of its Phase II trial evaluating bavitu...
Oct 20, 2008
TUSTIN, Calif., Oct 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today announced that it has completed enrollment in the first stage of its Phase II trial evaluating a com...
Oct 13, 2008
CAPE TOWN, South Africa and TUSTIN, Calif., Oct 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today reported the company's anti-phosphatidylserine (anti-PS) technology platf...
Oct 7, 2008
TUSTIN, Calif., Oct 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has completed enrollment in the first stage of a Phase I...
Sep 17, 2008
TUSTIN, Calif., Sept 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that on September 16, 2008, it received a letter from Nasdaq in...
Sep 9, 2008
TUSTIN, Calif., Sept 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2009 ended July 31, 2008. The company reported a consolidated net loss of $5,086,000, or $0.02 per basic and diluted share, compared to a consolida...
Sep 3, 2008
TUSTIN, Calif., Sept 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year 2009 on September 9, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT...
Aug 11, 2008
TUSTIN, Calif., Aug 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The new tr...
Jul 23, 2008
TUSTIN, Calif., July 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that it received a Staff Determination letter from the Nasdaq Stock Market (NASDAQ) on July 22, 2008 indicating that the company is not in compliance with the $1.00 minimum bid price requirement for continu...
Jul 14, 2008
TUSTIN, Calif., July 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced financial results for fiscal year (FY) 2008 ended April 30, 2008. Total revenues for FY 2008 increased 64% to $6,093,000, primarily reflecting increased sales by Avid Bioservices, the company's wholly owned...
Jul 9, 2008
TUSTIN, Calif., July 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its fiscal year 2008 financial results on July 14, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day. Peregrin...
Jul 2, 2008
TUSTIN, Calif., July 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical trial in patients with metastatic breast cancer. The trial is an open-label, Sim...
Jul 1, 2008
TUSTIN, Calif., July 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced it has entered into a five-year contract worth up to $44.4 milli...
Jun 30, 2008
TUSTIN, Calif., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC...
Jun 25, 2008
Leiden, The Netherlands/Parsippany, USA, 25 June 2008 - DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Avid Bioservices, Inc. of Tustin, California to join their Vendor Network. Under the terms of the agreement, Avid will be a pre-approved contract manufactu...
Jun 16, 2008
TUSTIN, Calif., June 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), today reported the issuance of two U.S. patents that significantly broaden the ...
Jun 2, 2008
CHICAGO and TUSTIN, Calif., June 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at th...
May 31, 2008
CHICAGO and TUSTIN, Calif., May 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical researchers from the Abramson Cancer Center of the University of Pennsylvania will present data showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at...
May 13, 2008
TUSTIN, Calif., May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported that two independent studies recently published in the journal Sc...
Apr 29, 2008
TUSTIN, Calif., April 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that it has completed enrollment in the first stage of its Pha...
Apr 15, 2008
SAN DIEGO and TUSTIN, Calif., April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that preclinical studies being presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) confirm a unique mechanism by which bavituximab, its lead anti-phospha...
Apr 15, 2008
SAN DIEGO and TUSTIN, Calif., April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that a preclinical study presented yesterday at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) demonstrates the vaccine-like ability of immunocytokine proteins combini...
Apr 15, 2008
SAN DIEGO and TUSTIN, Calif., April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the ...
Apr 14, 2008
SAN DIEGO and TUSTIN, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today that a preclinical study being presented by an independent team of investigators at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) further illustrates the broad...
Apr 11, 2008
TUSTIN, Calif., April 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of o...
Mar 11, 2008
TUSTIN, Calif., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the third quarter of fiscal year (FY) 20...
Mar 11, 2008
TUSTIN, Calif., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today released an update from two clinical trials assessing its targeted therapy Cot...
Mar 4, 2008
TUSTIN, Calif., March 4, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the third quarte...
Mar 3, 2008
TUSTIN, Calif., March 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today reported publication of a new preclinical study in Clinical Cancer Research tha...
Mar 2, 2008
Mar 2, 2008 By:Pete Gagnon, Frank Hensel, Richard Richieri BioPharm International Supplements ABSTRACT The affinity capture paradigm that dominates industrial IgG purification has proven unsuitable for IgMs because, in most cases, they are affected adversely by harsh elution conditions. The large size of IgMs is also a ...
Feb 12, 2008
TUSTIN, Calif., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient dosing has begun in its clinical trial designed to eva...
Feb 8, 2008
TUSTIN, Calif., Feb 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), today reported that clinical data on its anti-phosphatidylserine (anti-PS) monoc...
Feb 7, 2008
TUSTIN, Calif., Feb 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present at the 10th Annual BIO CEO & Inves...
Jan 29, 2008
TUSTIN, Calif., Jan 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient screening has begun in a clinical trial designed to ev...
Jan 23, 2008
TUSTIN, Calif., Jan 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has received a letter from the Nasdaq Stock Market (NASD...
Jan 23, 2008
TUSTIN, Calif., Jan 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that its Phase II clinical protocol to study bavituximab in comb...
Jan 22, 2008
TUSTIN, Calif., Jan 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that its Phase II clinical protocol to study bavituximab in comb...
Dec 20, 2007
TUSTIN, Calif., Dec 20, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today confirmed that its plans for advancing all three of its lead clinical prog...
Dec 14, 2007
TUSTIN, Calif., Dec 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced the sudden termination of its negotiations to finalize a contrac...
Dec 10, 2007
TUSTIN, Calif., Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the second quarter of fiscal year 2008 end...
Dec 5, 2007
-- Signs cGMP Manufacturing Agreement to Produce Clinical Supplies for ARIUS' Lead Antibody Targeting CD44 --TUSTIN, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Avid Bioservices, Inc. today announced it has signed a manufacturing supply and technology transfer agreement with ARIUS Research, Inc. (TSX: ARI). The agreement covers ARIUS' lead...
Dec 3, 2007
TUSTIN, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the second quarter of fiscal year 2008 on Decem...
Nov 26, 2007
--Addition of New Study Site at Leading Urban Medical Center Will Expand the Eligible Patient Pool for the Ongoing Bavituximab HCV/HIV Co-Infection Trial----Dr. Sulkowski, Principal Investigator of The Johns Hopkins Study Site, Has Expertise in Studying HCV Infection in HIV Patients--TUSTIN, Calif., Nov. 26 /PRNewswire-First...
Nov 16, 2007
-Republic of Georgia Drug Agency Approves Protocol for New Clinical Trial of Bavituximab in Combination with Docetaxel - TUSTIN, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HC...
Nov 13, 2007
-- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective Human Anti-VEGF Antibody Developed by Peregrine in Association with Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established Tumors in a Preclinical Breast Cancer Model ---- R84 Is Being Advanced as a Potential Clinical Candidate -- BOST...
Nov 5, 2007
- Bavituximab Appeared Generally Safe and Well Tolerated at All Doses Tested -- Signs of Anti-viral Activity Seen at All Dose Levels - - Exploratory Analysis of Cytokine Profile Following Treatment Supports Proposed Immunomodulatory Mechanism of Action -TUSTIN, Calif. and BOSTON, Nov. 5 /PRNewswire-FirstCall/ -- ...
Oct 30, 2007
TUSTIN, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Con...
Oct 22, 2007
TUSTIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a Phase II clinical protocol with the Ministry of Health of the Republi...
Oct 10, 2007
TUSTIN, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the first patient has been dosed in a clinical trial designed to evaluate the safety and ph...
Oct 5, 2007
- Presentation to Be Webcast Live On Company's Website -TUSTIN, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present...
Sep 10, 2007
TUSTIN, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a clinical protocol with the Drug Controller General of India (DCGI) f...
Sep 10, 2007
TUSTIN, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the first quarter of fiscal year 2008 ended July 31, 2007. ...
Sep 7, 2007
- Adding Bavituximab to Standard Regimen of Androgen Deprivation and Chemotherapy Reduced Size of Formerly Resistant Tumors by More than Half - - Data Further Confirm Bavituximab's Potential to Enhance Multiple Combination Regimens for Cancer Therapy - ATLANTA, and TUSTIN, Calif., Sept. 7 /PRNewswire-First...
Sep 4, 2007
- Bavituximab Equivalent Combined With Radiation Reduced Tumor Growth by 80% in Preclinical Lung Cancer Model - - Findings Confirm Key Aspects of Bavituximab's Mechanism of Action in Combination with Radiation Therapy - - Results Further Support Future Clinical Trials Tes...
Sep 4, 2007
TUSTIN, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its first quarter FY 2008 financial results ended July 31, 20...
Aug 7, 2007
-Final Data from Repeat Dose Trial to Be Presented at The Liver Meeting®, the Premier Event in the Science and Practice of Hepatology- TUSTIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies f...
Aug 2, 2007
- Access to Large Population of Glioblastoma Patients Expected to Support Rapid Enrollment in Phase ll Study of Promising New Approach -TUSTIN, Calif., Aug 02, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targete...
Jul 26, 2007
-Brings Two Decades of Hands-On Global Experience at Leading Firms to Business Development Team-TUSTIN, Calif., July 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatiti...
Jul 25, 2007
- Listed Companies Are Afforded Up To 360 Days to Regain Compliance with Minimum Bid Price Rule Under Nasdaq Marketplace Rules - TUSTIN, Calif., July 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatme...
Jul 23, 2007
- U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations - TUSTIN, Calif., July 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical...
Jul 11, 2007
TUSTIN, Calif., July 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a clinical protocol with the Drug Controller General of Indi...
Jul 11, 2007
TUSTIN, Calif., July 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the fiscal year ended April 30, 2007. The company reported ...
Jul 10, 2007
TUSTIN, Calif., July 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced initiation of patient enrolment in a study of bavituximab in patients co-infected ...
Jul 9, 2007
-Naturally-Occurring Anti-Angiogenesis Protein 'Clipped' Beta 2 Glycoprotein 1 Has Been Independently Validated in Cancer Models by Researchers at M. D. Anderson and Other Institutions- -Research Reported by a Group of Authors that Included Angiogenesis Pioneer Dr. Judah Folkman Showed that Treatment with 'Clipped' Beta 2 Glycoprotein 1 Resulted...
Jul 3, 2007
TUSTIN, Calif., July 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its fourth quarter and full year FY 2007 financial results on ...
Jun 28, 2007
TUSTIN, Calif., June 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has obtained commitments from several institutional investors to purchase ...
Jun 26, 2007
- Veteran Cotara Researcher Dr. Sunil Patel Opens New U.S. Clinical Trial Site -TUSTIN, Calif., June 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted antibodies for the treatment of cancer and hepatitis C virus infec...
Jun 25, 2007
- Access to Large Population of Glioblastoma Patients in India Expected to Support Rapid Enrollment in Phase II Safety and Efficacy Study of Promising Investigational Brain Cancer Therapy - - Results from This Study are Expected to Help Advance Cotara Toward Phase III Product Registratio...
May 31, 2007
50% of All Evaluable Patients Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable Disease 75% of Patients Receiving Combination of Bavituximab Plus Gemcitabine Achieved Objective Tumor Response or Stable Disease 50% ...
May 31, 2007
Terms of the Agreement Provide for Peregrine to Receive Development Fees and Potential Royalties That Could Exceed $50 MillionTUSTIN, Calif., May 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies fo...
May 17, 2007
Trial to Evaluate Potential of Bavituximab in Important HCV Population Representing Up to 30% of All U.S. HIV Patients TUSTIN, Calif., May 17 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted antibodies for the treatm...
Apr 20, 2007
New Study Demonstrated the Clinical Potential of Peregrine's Unique Selective Anti-VEGF Antibodies, Which Were as Effective as Avastin® in Animal Cancer Models Trials Could Begin as Soon as Next Year Robust Anti-Tumor Data Confirmed Broad Versatility of Clinical Stage Anti-P...
Apr 18, 2007
Immunization with a Bavituximab Equivalent and Irradiated Tumor Cells Increased Long-Term Survival to 57% From 0% in Controls in a Preclinical Model of Brain Cancer Survival Data Suggest that 99.99% of Tumor Cells in These Animals Were Destroyed ...
Apr 18, 2007
New Studies Confirm That Fusion Proteins Made by Combining Cytokines With Peregrine's Anti-PS Antibodies Demonstrate Increased Anti-Tumor Activity With No Observable Toxicity These Immunocytokine Fusion Proteins Were Developed Using Peregrine's Proprietary Vascular Targeting Agent (VTA)...